SeedCue

Interviews

Interviews with those who change the game
Gallery inside!

Antiverse, UK-based biotech developing AI-designed therapeutic antibodies for undruggable disease targets, closed a Series A round of $9.3 million. The round was led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures and existing investors DBW, Kadmos Capital and i&i Biotech Fund.

Authors

Oana Modorcea
Founder & Managing Editor